Deuremidevir Hydrobromide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Deuremidevir Hydrobromide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Deuremidevir Hydrobromide can convert its Small molecule drug profile and RdRp biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Deuremidevir Hydrobromide (query alias: Deuremidevir Hydrobromide) |
|---|---|
| Modality / target | Small molecule drug; RdRp; RdRp inhibitors |
| Highest global status | Approved |
| Originator | Shanghai Junshi Biosciences Co., Ltd., Shanghai Vinnerna Biosciences Co., Ltd. |
| Active developers | Shanghai Institute of Materia Medica Chinese Academy of Sci, Wuhan Institute of Virologychinese Academy, Suzhou Vigonvita Life Sciences Co.,Ltd |
The MCP disease footprint includes COVID-19, Respiratory Syncytial Virus Infections, Henipavirus Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07402512 | Phase 3 | Recruiting | 498 | The earliest time from the first dose to the sustained resolution of 6 RSV infection-related clinical signs and symptoms |
| CTR20261184 | Phase 1 | 已完成 | 48 | Not disclosed |
| NCT06749236 | Phase 1 | Completed | 18 | Cmax |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment
Phase 3; n=345; evaluation: Negative. Reported fields: Viral load rebound (VLR) = 21.7 half-log increase in viral RNA copies per milliliter ; Viral load rebound (VLR) = 20.0 half-log increase in viral RNA copies per milliliter
君实生物新冠口服药民得维®第2项三期研究结果荣登《柳叶刀-感染病学》
临床3期; n=1296; evaluation: 积极. Reported fields: 临床缓解(期中分析) = 临床症状的消失时间，中位时间比安慰剂组缩短2天 ; 临床缓解(期中分析) = 临床症状的消失时间，中位时间比安慰剂组缩短2天
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
Phase 3; n=822; evaluation: Positive. Reported fields: Incidence of adverse events = 77.3 % ; Incidence of adverse events = 67.4 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Deuremidevir Hydrobromide addresses COVID-19, Respiratory Syncytial Virus Infections, Henipavirus Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-12-03 | 先声药业与旺山旺水就氢溴酸氘瑞米德韦抗RSV感染等新适应症达成独家许可合作 | Approved | Financial terms not disclosed |
| 2023-02-08 | 四環醫藥旗下子公司吉林四環製藥与上海旺實生物达成合作协议 | Approved | Financial terms not disclosed |
| 2023-01-31 | 上海君实生物医药科技股份有限公司自愿披露关于与华海药业签署产品委托生产及供货协议的公告 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
